Psilocybin Therapy for Depression in Parkinson's Disease
This study is looking at whether psilocybin (a drug) can help improve depression in people with Parkinson's disease. You might be able to join if you are 40 to 80 years old, have been diagnosed with Parkinson's disease, and are currently experiencing symptoms of depression. Participants will receive a single dose of psilocybin, ranging from a low "microdose" to a higher dose, along with psychological support. Some participants will also receive pimavanserin or a placebo (an inactive substance). The main goal is to see if psilocybin improves depression symptoms within 30 days after the first dose. The current status of this study is unclear.
- Study design
- This is a randomized controlled trial planning to enroll 60 participants. It will compare psilocybin with psychological support to pimavanserin or a placebo.
- What's involved
- You would attend in-person visits at UCSF, complete two drug administration sessions, and have psychotherapy sessions before and after each drug dose. You will also have clinical assessments, brain imaging, non-invasive brain stimulation, and blood draws.
- Compensation
- Not stated in the trial record.
- Follow-up
- Follow-up will continue for 3 months after the second drug administration session.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Psilocybin Therapy for Depression in Parkinson's Disease
At a glance
Conditions
NCT06455293
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Joshua Woolley, MD,PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
- Ellen Bradley, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Evaluate the efficacy of psilocybin for improving depression in people living with Parkinson's diseaseBaseline to 30 days after first drug dose
Changes in depression as measured by the MADRS